公开(公告)号：US11708330B2

公开(公告)日：2023-07-25

申请号：US16642059

申请日：2018-08-30

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Sucheta Telang ,  Jason Chesney ,  John O. Trent ,  Joseph A. Burlison

IPC: C07D215/42 ,  A61P35/00 ,  A61K9/00

CPC classification number: C07D215/42 ,  A61P35/00 ,  A61K9/0019 ,  A61K9/0053

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

公开(公告)号：US11679098B2

公开(公告)日：2023-06-20

申请号：US16597027

申请日：2019-10-09

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Paula J. Bates ,  Sarah A. Andres ,  Joseph A. Burlison ,  Levi Beverly ,  Nagaraju Miriyala

IPC: A61K31/045 ,  A61K31/4188 ,  A61K31/08 ,  A61K31/035 ,  A61K31/351 ,  A61K31/133 ,  A61K31/085 ,  A61K31/095 ,  A61K31/22 ,  A61K31/121

CPC classification number: A61K31/4188 ,  A61K31/035 ,  A61K31/045 ,  A61K31/08 ,  A61K31/085 ,  A61K31/095 ,  A61K31/121 ,  A61K31/133 ,  A61K31/22 ,  A61K31/351

Abstract: Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

公开(公告)号：US20210137939A1

公开(公告)日：2021-05-13

申请号：US17053057

申请日：2019-05-10

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Geoffrey J. Clark ,  John O. Trent ,  Joseph A. Burlison

IPC: A61K31/55 ,  A61K31/40 ,  A61K31/357

Abstract: A compound for use in treating a disease associated with activating mutations in RAS, or for use in treating a disease treatable by a reduction in RAS activity, is selected from a compound of Formula (I), salts and esters thereof. The compounds are particularly useful in treating cancer.

公开(公告)号：US11312690B2

公开(公告)日：2022-04-26

申请号：US15746819

申请日：2016-07-22

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Geoffrey J. Clark ,  John O. Trent ,  Joseph A. Burlison ,  Nagaraju Miriyala

IPC: C07D239/95 ,  A61P35/04

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

公开(公告)号：US10774046B2

公开(公告)日：2020-09-15

申请号：US16170391

申请日：2018-10-25

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Sucheta Telang ,  Jason Chesney ,  John O. Trent ,  Joseph A. Burlison ,  Nagaraju Miriyala

IPC: C07D215/46 ,  C07D215/42 ,  A61P35/00 ,  A61K45/06 ,  A61K31/4706

Abstract: Some embodiments of the invention include inventive compounds. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Other embodiments include PFKFB4 inhibitors and methods of using the same that can target neoplastic cells, including, such as, mechanisms within those cells that relate to the use of the glycolytic pathway. In other embodiments, small molecule PFKFB4 inhibitors are used to disrupt the kinase domain of PFKFB4 and, in some instances, decrease the glucose metabolism and growth of human cancers. Additional embodiments of the invention are also discussed herein.